Bastide’s HY top-line looks promising overall. The FY outlook was adjusted given the in-process sale of the loss-making Livramedom subsidiary but only minor changes are expected to our P&L estimates.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bastide’s HY top-line looks promising overall. The FY outlook was adjusted given the in-process sale of the loss-making Livramedom subsidiary but only minor changes are expected to our P&L estimates.
